THE EFFECT OF MULTIPLE DOSES OF PF-06835919 ON THE PHARMACOKINETICS OF A SINGLE ORAL MIDAZOLAM DOSE IN HEALTHY PARTICIPANTS
Status:
Completed
Trial end date:
2019-06-25
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, open label, 2 way crossover drug drug interaction (DDI) study
which will evaluate the impact of PF 06835919 on midazolam pharmacokinetics in healthy
participants. Participants will be randomized to 1 of 2 treatment sequences as described
below. A total of approximately 10 healthy male and/or female participants will be enrolled
in this study so that approximately 5 participants will be enrolled into each treatment
sequence. In this crossover study, 2 treatments are being assessed.